The Medicines Company – Strategy, SWOT and Corporate Finance Report

The Medicines Company – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company

Key Highlights

The Medicines Company (TMC) is a biopharmaceutical company that focuses on developing and commercializing novel therapies to address the unmet medical need for atherosclerotic cardiovascular disease (ASCVD). It is investigating a RNA interference (RNAi) therapeutic, inclisiran, for the treatment of ASCVD. Its inclisiran exclusively inhibits production of proprotein convertase subtilisin or kexin type 9 (PCSK9), a key protein that controls LDL-cholesterol (LDL-C) levels. TMC is also evaluating an investigational candidate for the treatment of homozygous familial hypercholesterolemia (HoFH). The company holds the rights to develop, manufacture, and commercialize inclisiran through a license agreement with Alnylam Pharmaceuticals Inc. TMC is headquartered in New Jersey, the US.

Scope

Detailed information on The Medicines Company required for business and competitor intelligence needs

A study of the major internal and external factors affecting The Medicines Company in the form of a SWOT analysis

An in-depth view of the business model of The Medicines Company including a breakdown and examination of key business segments

News about The Medicines Company, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of The Medicines Company and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess The Medicines Company as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on The Medicines Companys business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Sanofi

RegenxBio Inc

Regeneron Pharmaceuticals Inc

Merck & Co Inc

Ionis Pharmaceuticals Inc

Gemphire Therapeutics Inc

Esperion Therapeutics Inc

Amgen Inc

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

The Medicines Company - Key Facts

The Medicines Company - Key Employees

The Medicines Company - Key Employee Biographies

The Medicines Company - Major Products and Services

The Medicines Company - History

The Medicines Company - Company Statement

The Medicines Company - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 Company Analysis

Company Overview

The Medicines Company - Business Description

Geographical Segment: Europe

Performance

Geographical Segment: Other

Performance

Geographical Segment: The US

Performance

R&D Overview

The Medicines Company - Corporate Strategy

The Medicines Company - SWOT Analysis

SWOT Analysis - Overview

The Medicines Company - Strengths

The Medicines Company - Weaknesses

The Medicines Company - Opportunities

The Medicines Company - Threats

The Medicines Company - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences Financial Deals and Alliances

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

The Medicines Company, Recent Deals Summary

Section 5 Company’s Recent Developments

Apr 25, 2019: The Medicines Company reports first-quarter 2019 financial results and significant progress with the Inclisiran clinical development program

Feb 27, 2019: The Medicines Company announces fourth-quarter and full year 2018 business and financial results

Nov 08, 2018: The Medicines Company reports third-quarter 2018 results

Aug 01, 2018: The Medicines Company Reports Second-Quarter 2018 Results

May 10, 2018: OU-Led Research Team Accelerating Antibiotic Discovery

Apr 25, 2018: The Medicines Company Reports First-Quarter 2018 Results

Mar 27, 2018: The Medicines Company Announces Chief Financial Officer Transition

Feb 27, 2018: The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors

Feb 21, 2018: The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

The Medicines Company, Key Facts

The Medicines Company, Key Employees

The Medicines Company, Key Employee Biographies

The Medicines Company, Major Products and Services

The Medicines Company, History

The Medicines Company, Subsidiaries

The Medicines Company, Key Competitors

The Medicines Company, Ratios based on current share price

The Medicines Company, Annual Ratios

The Medicines Company, Annual Ratios (Cont…1)

The Medicines Company, Annual Ratios (Cont…2)

The Medicines Company, Interim Ratios

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

The Medicines Company, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

The Medicines Company, Performance Chart (2014 – 2018)

The Medicines Company, Ratio Charts

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports